- Home
- NGNE vs ASLE Comparison
NGNE vs ASLE Comparison
Compare NGNE & ASLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- ASLE
- Stock Information
- Founded
- NGNE 2003
- ASLE 2008
- Country
- NGNE United States
- ASLE United States
- Employees
- NGNE N/A
- ASLE N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- ASLE Industrial Specialties
- Sector
- NGNE Health Care
- ASLE Consumer Discretionary
- Exchange
- NGNE Nasdaq
- ASLE Nasdaq
- Market Cap
- NGNE 325.3M
- ASLE 277.0M
- IPO Year
- NGNE N/A
- ASLE N/A
- Fundamental
- Price
- NGNE $20.51
- ASLE $8.51
- Analyst Decision
- NGNE Strong Buy
- ASLE Buy
- Analyst Count
- NGNE 7
- ASLE 3
- Target Price
- NGNE $41.86
- ASLE $8.33
- AVG Volume (30 Days)
- NGNE 123.0K
- ASLE 480.2K
- Earning Date
- NGNE 08-11-2025
- ASLE 08-06-2025
- Dividend Yield
- NGNE N/A
- ASLE N/A
- EPS Growth
- NGNE N/A
- ASLE N/A
- EPS
- NGNE N/A
- ASLE 0.13
- Revenue
- NGNE N/A
- ASLE $350,583,000.00
- Revenue This Year
- NGNE N/A
- ASLE $2.54
- Revenue Next Year
- NGNE N/A
- ASLE $16.24
- P/E Ratio
- NGNE N/A
- ASLE $67.21
- Revenue Growth
- NGNE N/A
- ASLE N/A
- 52 Week Low
- NGNE $6.88
- ASLE $4.53
- 52 Week High
- NGNE $74.49
- ASLE $8.91
- Technical
- Relative Strength Index (RSI)
- NGNE 47.72
- ASLE 77.90
- Support Level
- NGNE $18.94
- ASLE $8.40
- Resistance Level
- NGNE $21.59
- ASLE $8.91
- Average True Range (ATR)
- NGNE 1.40
- ASLE 0.37
- MACD
- NGNE -0.26
- ASLE 0.24
- Stochastic Oscillator
- NGNE 32.30
- ASLE 87.26
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About ASLE AerSale Corporation
AerSale Corp is an integrated, diversified leader in aviation aftermarket products and services. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. The company operating segment includes Asset Management Solutions and TechOps. It generates maximum revenue from the Asset Management Solutions segment.